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Metabolic syndrome (MS) is a cluster of glucose intolerance, hypertension, and dyslipidemia with visceral fat accumulation.
This study was undertaken to assess which components of metabolic syndrome (MS), including uric acid and proinﬂammatory
markers, are related to adiponectin levels in overweight and obese women with MS. Ninety-one women (60 with MS and 31
controls) were assessed in relation to classical and inﬂammatory parameters of MS. In comparison to controls, patients with MS
showed signiﬁcant diﬀerences in parameters that are typically associated with MS and in inﬂammatory markers. Fibrinogen, CRP,
and C3 were positively, whereas albumin was inversely correlated with abdominal adiposity and insulin resistance. Adiponectin
was inversely correlated with waist circumference and uric acid levels. Activities of adiponectin and proinﬂammatory markers are
not correlated in overweight and obese women with MS. In addition to abdominal adiposity, uric acid may be implicated in a
decrease of adiponectin in MS patients.
1.Introduction
Metabolic syndrome (MS) is a disorder comprised of a com-
bination of glucose intolerance, hypertension, dyslipidemia,
and visceral fat accumulation, which promotes the develop-
ment of cardiovascular diseases and atherosclerosis [1, 2].
Abdominalobesityandinsulinresistancearethecorefea-
tures of MS. Inﬂammation, demonstrated primarily by
elevated levels of serum C-reactive protein, is thought to
be associated with insulin resistance and MS [3–5]. Central
obesity is considered to be one of the most important
determinants of the low-grade chronic inﬂammation present
in MS [6].
Adipose tissue produces proinﬂammatory cytokines,
such as interleukin 6 (IL-6), tumor necrosis factor-α (TNF-
α), and complement factors [7]. However, this tissue also
secretes adiponectin, a protein showing antiinﬂammatory
activity, which inhibits TNF-α production [8], adhesion
molecule expression, and nuclear transcriptional factor κB
signaling, a pivotal pathway in inﬂammatory reactions in
endothelial cells [9, 10]. In addition, adiponectin is anti-
atherogenicandisaninsulin-sensitizingagent[11].Adipose-
derivedTNF-αmayhavenegativeeﬀectsontheexpressionof
adiponectin and vice versa, and these two proteins also have
opposite eﬀects on insulin sensitivity [12, 13]. Given this
antagonisticrelationship,obesity,andespeciallyvisceralobe-
sity,mayleadtoadecreasedsecretionofadiponectinthrough
feedbackinhibition,therebysuppressingthebeneﬁcialeﬀects
of adiponectin on insulin sensitivity.
Levels of adiponectin are lower in patients with obesity
[14], type 2 diabetes mellitus [15], arterial hypertension
[16]a n dM S[ 17, 18]. Decreases in serum adiponectin levels
are associated with diﬀerent components of MS, and the
decreased adiponectin levels appear to be related to increases
in the number of MS components in both sexes [18].2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
In MS pathophysiology, it is unclear whether decreased
anti-inﬂammatory adiponectin and increased proinﬂamma-
tory markers are associated and occur simultaneously in the
development of this syndrome. Some studies have found
inverse relationships between adiponectin concentrations
and proinﬂammatory markers [19, 20] .H o w e v e r ,ar e c e n t
study showed that adiponectin levels and proinﬂammatory
status are independent [21].
Severalstudieshavedemonstratedtheimportanceofuric
acid in the physiopathology of MS [22, 23]. In a previous
study, we veriﬁed a correlation between serum uric acid level
a n ds e v e r a lc o m p o n e n t so fM S ,a sw e l la si t si n ﬂ u e n c eo n
oxidative stress and antioxidant defense [24]. Nevertheless,
few studies to date have assessed the association of uric acid
levels with adiponectinemia in MS.
The knowledge of whether proinﬂammatory markers
and uric acid levels are connected with adiponectin could
be important to both the pathophysiology and therapy of
MS patients. Therefore, the aim of the present work was to
assess which components of MS, including uric acid, and
proinﬂammatory markers, are related to adiponectin levels
in overweight and obese women with MS.
2.SubjectsandMethods
2.1. Subjects. Ninety-one women, selected from ambulatory
patients and workers of the University Hospital of Londrina,
Paran´ a, Brazil, were chosen to participate in the study. The
control group included 31 healthy women, whereas the MS
group was made up of 60 overweight and obese women
with MS. All women in the control group had a body
mass index (BMI) between 20 and 25kg/m2 and did not
present any of the metabolic syndrome parameters listed in
the deﬁnition below. Control group and MS group had 6
and 16 postmenopausal women, respectively. Furthermore,
studysubjectswerenotregularlytakinganymedications.The
groups were paired by age, race, smoking habit, and alcohol
intake. Information on the lifestyle factors and medical
history of the study subjects were obtained through a clinical
evaluation.
MS was deﬁned following the Adult Treatment Panel
III criteria [25], when three of the following ﬁve char-
acteristics were conﬁrmed: (1) abdominal obesity: waist
circumference ≥102cm in men and ≥88cm in women;
(2) hypertriglyceridemia ≥150mg/dL (1.695mmol/L); (3)
low HDL cholesterol levels ≤ 40mg/dL (1.036mmol/L) in
men and ≤50mg/dL (1.295mmol/L) in women; (4) high
blood pressure (≥130/85mmHg); (5) high fasting glucose
(≥110mg/dL).
None of the participants of the study presented thyroid,
renal, hepatic, gastrointestinal, or oncological diseases, and
none of the participants had a clinically evident infection
or were receiving drugs for hyperglycemia, drugs known to
aﬀect lipoprotein and uric acid metabolism or inﬂammatory
markersorhormonereplacementtherapyforatleast4weeks
before the study. All patients provided written informed
consent, and the study protocol was fully approved by the
Ethical Committee of the University of Londrina (Paran´ a,
Brazil).
2.2. Anthropometric and Arterial Pressure Measurements.
Height and weight were measured in the morning with
subjects wearing light clothing but no shoes. After 5 minutes
of rest, each subject had his/her blood pressure measured
from the left arm with the subject in a sitting position. We
considered the current use of antihypertensive medication to
be an indication of high-blood pressure. Body mass index
(BMI) was calculated as weight (Kg) divided by height (m)
squared. Waist circumference was measured with a soft tape
on standing subjects midway between the lowest rib and the
iliac crest.
2.3. Biochemical Measurements. A f t e rf a s t i n gf o r1 2h o u r s ,
the patients underwent laboratory blood analyses for the
following factors: plasma glucose and serum total choles-
terol (TC), high-density lipoprotein cholesterol (HDL-
cholesterol), low-density lipoprotein cholesterol (LDL-
cholesterol), triacylglycerol (TG), and uric acid and albumin
levels, which were evaluated by a biochemical auto-analyzer
(Dimension Dade AR) using Dade Behring kits. Plasma
insulin levels were determined by microparticle enzyme
immunoassay (MEIA, AXSYM, ABBOTT Laboratory, Wies-
baden, Germany). All samples were centrifuged at 3.000rpm
for 15 minutes and plasma or serum aliquots were stored
at −70◦C until they were assayed. Interassay coeﬃcient of
variation (CV) for all assays were <10% as determined in
human serum.
The homeostasis model assessment (HOMA) was used
as a surrogate measure of insulin sensitivity [26] using the
following equation: HOMA-IR = insulin fasting (μU/mL) ×
glucose fasting (nmol/L)/22.5.
2.4. Measurement of Inﬂammatory Markers and Cytokines.
The total counts of leucocytes was determined using Cell-
Dyn 3700 (ABBOTT Laboratory); plasmatic ﬁbrinogen was
measured by the Klauss method; hsCRP (highly sensitive
CRP) and serum complement factors C3 and C4 levels
were measured using a nephelometric assay (Behring Neph-
elometer II, Dade Behring, Marburg, Germany). Serum
TNF-α, IL-6, and adiponectin levels were measured by
a sandwich enzyme-linked immunosorbent assay (ELISA)
using a commercial immunoassay (R&D System).
2.5. Statistical Analysis. Data were expressed as the median
values (minimum and maximum). Comparisons between
control subjects and patients with MS were conducted using
the Mann-Whitney test. Correlations were evaluated by
Spearman’s rank correlations. The results were considered to
be signiﬁcant when P<0.05. A statistical software program
Graph Pad InStat (Graph Pad Software, Inc) was used for
analyses.
3. Results
Subjects in both groups did not drink alcohol regularly.
Clinical and biochemical characteristics of the subjects are
shown in Table 1. There were no diﬀerences related to
age or smoking between the groups. Analyses performed
withoutpostmenopausalwomendidnotverifyanystatisticalJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
Table 1: Clinical and laboratory characteristics of patients with metabolic syndrome and controls.
Metabolic Syndrome
(n = 60) Controls (n = 31) P
Age (years) 45.0 (25.0–60.0) 41.5 (25.0–54.0) 0.1257
Smoking/no smoking 2/58 1/30 0.6379
BMI (m/kg2) 37.2 (27.1–53.9) 22.9 (20.1–24,5) <0.0001
WC (cm) 110.0 (88.0–157.0) 79.0 (61.0–86.0) <0.0001
SBP (mmHg) 134.5 (99.0–203.0) 101.0 (81.0–130.0) <0.0001
DBP (mmHg) 83.0 (62.0–124.0) 65.0 (47.0–80.0) <0.0001
Triacylg (mg/dL) 202.0 (40.0–401.0) 70.0 (32.0–135.0) <0.0001
HDL (mg/dL) 39.0 (19.0–81.0) 58.5 (51.0–77.0) <0.0001
Fasting glucose (mg/dL) 100.5 (74.0–195.0) 80.0 (71.0–93.0) <0.0001
Fasting insulin (μU/mL) 18.50 (4.10–75.40) 4.40 (2.90–9.80) <0.0001
HOMA 4.47 (0.83–36.24) 0.84 (0.57–1.79) <0.0001
Uric acid (mg/dL) 5.51 (3.15–9.65) 3.38 (2.07–4.73) <0.0001
Data are median (minimum–maximum).
BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; Triacylg: triacylglycerol; HDL: High-density
lipoprotein; HOMA: Homeostasis model of assessment.
diﬀerence in relation to data shown in the present study.
The MS group of patients had signiﬁcantly higher BMI,
waist circumference, systolic and diastolic blood pressure,
triacylglycerol levels, fasting glucose and insulin, HOMA,
and uric acid levels than the control group (P<0.0001). The
MSgroupalsohadsigniﬁcantlylowerHDL-cholesterollevels
(P<0.0001; Table 1).
With regard to the levels of inﬂammatory markers,
patients with metabolic syndrome had signiﬁcantly higher
leukocytes counts (P = 0.0004), ﬁbrinogen (P = 0.0007), C-
reactive protein (P<0.0001), C3 and C4 (P<0.0001), and
IL-6 (P = 0.0373) concentrations and lower albumin levels
(P = 0.0146) than the control group. Serum adiponectin
levels were signiﬁcantly lower in the metabolic syndrome
group (P = 0.0001). TNF-α levels were not statistically
diﬀerent (P = 0.9952) between the groups (Table 2).
There were signiﬁcant correlations between several
parameters of metabolic syndrome and the levels of inﬂam-
matory markers (Table 3). Waist circumference was posi-
tively correlated with leukocyte counts (r = 0.25; P<0.05),
ﬁbrinogen (r = 0.45; P<0.0001), C-reactive protein (r =
0.51; P<0.0001), and C3 (r = 0.28; P<0.05), and
inversely correlated with serum albumin (r =− 0.37; P<
0.01) and adiponectin (r =− 0.21; P<0.05).
Diastolic blood pressure was positively correlated with
ﬁbrinogen (r = 0.30; P<0.05). There was no statisti-
callysigniﬁcant correlation between serum proinﬂammatory
cytokines TNF-α and IL-6 and any metabolic syndrome
parameter. Serum fasting insulin and insulin resistance
assessedbyHOMAwerepositivelycorrelatedwithﬁbrinogen
(r = 0.26; P<0.05), C-reactive protein (r = 0.29; P<0.05,
and r = 0.35; P<0.01, resp.), and C3 (r = 0.35; P<0.01,
and r = 0.42; P<0.001, resp.) and inversely correlated
with serum albumin (r =− 0.30; P<0.05, and r =
−0.29; P<0.05, resp.). Serum triacylglycerol levels were
positively correlated with C3 (r = 0.34; P<0.01), and C4
(r = 0.42; P<0.001; Table 3).
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Figure 1: Dispersion graphic between plasma levels of uric acid
and adiponectin in patients with metabolic syndrome (r =
−0.3752; P = 0.0170).
Serum adiponectin levels were not correlated with any
proinﬂammatory markers in the present study (Table 4).
However, serum uric acid levels were inversely correlated
with adiponectin (r =− 0.3752; P<0.0170; Figure 1).
4. Discussion
The major ﬁndings of the present study were that adi-
ponectin was inversely associated with uric acid levels and
that adiponectin and the activity of proinﬂammatory mark-
ers are not correlated in patients with MS. The present study
also evaluated several inﬂammatory markers in subjects with
MS. The results are in agreement with the literature, showing
thatpatientswithMSpresentahigherproinﬂammatorystate
and a decrease in anti-inﬂammatory mediators, shown by
reduced levels of adiponectin [4, 27].4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 2: Cytokines, inﬂammatory markers and adiponectin levels in patients with metabolic syndrome and controls.
Metabolic Syndrome
(n = 60) Controls (n = 31) P
Leukocytes (μL−1) 7700 (3500–13800) 6000 (3100–8600) 0.0004
Fibrinogen (mg/dL) 314.0 (185.0–489.0) 262.0 (188.0–314.0) 0.0007
CRP (mg/L) 7.80 (1.10–46.5) 0.70 (0.16–5.20) <0.0001
Albumin (g/dL) 4.41 (3.56–5.55) 4.74 (3.75–5.47) 0.0146
C3 (mg/dL) 202.8 (115.0–271.0) 126.0 (94.8–188.0) <0.0001
C4 (mg/dL) 43.20 (24.00–96.60) 23.50 (14.60–43.10) <0.0001
TNF-α (pg/mL) 32.69 (11.62–193.81) 38.71 (8.58–86.26) 0.9952
IL-6 (pg/mL) 3.96 (3.04–92.45) 3.32 (2.55–9.63) 0.0373
Adiponectin (μg/mL) 7.11 (3.19–18.22) 12.31 (9.11–27.27) 0.0001
Data are median (minimum-maximum).
CRP: C-reactive protein; C3: complement factor C3; C4: complement factor C4; TNF-α: tumor necrosis factor-α; IL-6: interleukin-6.
∗P ≤ 0.05, ¤P ≤ 0.01, ‡P ≤ 0.0001.
ThepresentworkalsoveriﬁedthatasidefromC4,TNF-α,
and IL-6, inﬂammatory markers were associated with waist
circumference and insulin resistance, emphasizing that this
syndrome is proinﬂammatory. Therefore, aside from CRP,
both positive (ﬁbrinogen and C3) and negative acute phase
reactant proteins (albumin) can be considered inﬂammatory
markers of good accuracy in MS.
Abdominal subcutaneous tissue produces a variety of
adipokines, such as TNF-α and IL-6, which has an important
role in inﬂammation and insulin resistance via endocrine,
paracrine, or autocrine signals [28–30]. Interleukin-6 (IL-
6) is considered to be the major mediator of the hepatic
acute-phase reaction and is thought to play a central role in
the pathogenesis of cardiovascular disease in patients with
insulin resistance [31]. The data in the present study are
consistent with those in the literature which show that CRP
is more closely related to glucose metabolism alteration than
IL-6, since CRP has a signiﬁcantly increased half life in
relation to IL-6 [32].
Although serum IL-6 levels were signiﬁcantly higher in
the patients with MS than in controls in the current study,
levels of TNF-α were not found to be higher in MS patients.
TNF-α does not seem to be released into the circulation
and is, thus, unable to signal systematically [33, 34], thus,
functioning as a paracrine pathway [12]. In accordance with
ap r e v i o u ss t u d y[ 27], our data also showed that the level of
serum TNF-α is not an appropriate inﬂammatory marker in
patients with MS.
Adipose tissue is a direct source of complement factors.
Several studies have shown that complement factors strongly
predict cardiovascular events in adolescents and adults
[35, 36]. Central obesity in particular seems to trigger C3
production [36]. The results of the current study conﬁrmed
the ﬁndings of the correlation between central obesity and
C3. Moreover, C3 is also correlated with insulin resistance
and triacylglycerol.
The results of the present study are in agreement with the
ﬁndings of a correlation between central obesity and CRP. In
addition, CRP was also correlated with fasting insulin and
insulin resistance veriﬁed by HOMA. Similarly to the results
of the current study, meta-analysis of prospective studies
showedapositive correlationbetweencoronaryheartdisease
and ﬁbrinogen, C-reactive protein, and leukocyte counts,
and a negative correlation with albumin [37]. Therefore, in
the present study, inﬂammatory markers were more closely
related to abdominal adiposity and insulin resistance than to
dyslipidemia and arterial hypertension.
As reported in other studies, lower levels of adiponectin
wereobserved in MS patients. Furthermore, adiponectin was
correlated with WC in MS patients but was not related to
any proinﬂammatory marker in either MS patients or in
the control group (data not shown). Yang et al. [38] also
showed that in subjects with BMI > 35kg/m2, adiponectin
levels were not signiﬁcantly related to most variables of
MS, except for the waist-to-hip ratio. They suggest that
this ﬁnding may simply imply that “body-weight factors”
could be more important than other factors in modulating
plasma adiponectin levels in their study. Matsushita et al.
[27] showed a stronger association between adiponectin and
parameters of MS than with IL-6, TNF-α, and even CRP. The
authors concluded that adiponectin plays a key role in the
development ofMSandthatdetermining serumadiponectin
levels is important for the prevention and treatment of this
syndrome.
Herder et al. [21]h a v en o tf o u n dac o r r e l a t i o nb e t w e e n
serum adiponectin and several proinﬂammatory markers
in patients with an impaired glucose tolerance and type
2 diabetes mellitus. The authors suggested that hypoad-
iponectinemia and low-grade inﬂammation are independent
and distinct factors.
In the meantime, a growing body of evidence indicates
that elevated uric acid levels are commonly associated with
cardiovascular disease, and uric acid has even been suggested
to have a causal role in hypertension and MS [23]. Uric acid
traverses dysfunctional endothelial cells and accumulates as
crystals within atherosclerotic plaques. These crystals may
contribute to local inﬂammation and plaque progression
[39]. Uric acid has been shown to activate leukocytes and
stimulates the production of interleukin 1-β, interleukin
6 (IL-6), and TNF-α by mononuclear cells, and CRP byJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
Table 3: Spearman’s Correlation coeﬃcients among inﬂammatory markers and the components of metabolic syndrome.
Leuk Fib CRP C3 C4 Alb TNF-α IL-6 ADIP
WC 0.25∗ 0.45‡ 0.51‡ 0.28∗ −0.07 −0.37¤ −0.15 0.07 −0.21∗
SBP 0.18 0.15 0.14 0.10 −0.05 −0.06 0.07 −0.06 0.09
DBP 0.21 0.30∗ 0.19 0.22 0.02 −0.01 0.01 0.17 −0.12
Triacylg 0.11 −0.22 0.04 0.34¤ 0.42† 0.11 0.10 0.10 −0.05
HDL 0.12 0.05 −0.02 −0.05 −0.10 0.01 0.05 0.06 0.15
Glucose 0.17 0.12 0.12 0.20 −0.01 −0.12 −0.04 −0.10 −0.10
Insulin 0.10 0.26∗ 0.29∗ 0.35¤ −0.10 −0.30∗ 0.04 0.13 −0.18
HOMA 0.21 0.26∗ 0.35¤ 0.42† −0.07 −0.29∗ −0.04 0.13 −0.18
Leuk: leukocytes; Fib: ﬁbrinogen; CRP: C-reactive protein; C3: Complement factor C3; C4: Complement factor C4; Alb: albumin; TNF-α: tumor necrosis
factor-α; IL-6: interleukin-6;Adip: adiponectin;WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; Triacylg: triacylglycerol;
HDL: High-density lipoprotein; HOMA: Homeostasis Model of Assessment.
∗P ≤ 0.05, ¤P ≤ 0.01, †P ≤ 0.001, ‡P ≤ 0.0001.
Table 4: Spearman’s Correlation coeﬃcients among adiponectin
and the inﬂammatory markers in patients with metabolic syn-
drome.
Adiponectin (n = 60)
RP
Leukocytes −0.291 .065
CRP −0.247 .119
Fibrinogen −0.126 .427
Albumin −0.065 .991
C3 −0.24 .134
C4 −0.12 .452
TNF-α −0.156 .330
IL-6 −0.002 .991
CRP: C-reactive protein; C3: complement factor C3; C4: complement factor
C4; TNF-α: tumor necrosis factor-α; IL-6: interleukin-6.
cultured human vascular cells [22, 39]. Nevertheless, our
data have not shown any signiﬁcant association between
uric acid levels and inﬂammatory markers, except for adi-
ponectin.
Patel et al. [40] also veriﬁed that adiponectin was
inversely associated with uric acid in apparently healthy
young adults. The authors concluded that the functional
metabolic role of adiponectin in this inverse relationship,
independent of the other known biologic factors such as
insulin resistance and visceral adiposity, was not clear.
Adiponectin was the unique inﬂammatory marker measured
in the current study that was correlated with serum uric acid
levels (an inverse correlation), and both were signiﬁcantly
altered in MS patients. On the other hand, adiponectin levels
were not correlated with uric acid levels in the control group
(data not shown).
Although uric acid may have a protective eﬀect due to
its antioxidant properties [38], it is clear that the dominant
eﬀe c to fu r i ca c i di nM Si sd e l e t e r i o u s .I ti ss t i l lu n c l e a r
which of the following detrimental roles of uric acid is more
important: mediating the eﬀects of conventional risk factors
in the development of the atherosclerotic disease, mediating
the eﬀects of an anti-inﬂammatory status, or mediating the
eﬀects of a proinﬂammatory status. Our data, which showed
an inverse relationship between adiponectin with WC and
uric acid levels, reinforce the former two hypotheses.
When considering the results of the present study, the
following limitations must be considered: ﬁrst, the small size
sample did not allow for a correction for multiple testing.
Second, the present study was performed with pre- and
postmenopausal women what could have interfered with
the results, although statistical analyses have not conﬁrmed
this likelihood. Third, some of the variables may have been
confounding. Therefore, the data shown in the present study
should be considered carefully. Nevertheless, we conducted
rigorous clinical and laboratorial assessments to ensure that
thecontrolandpatientgroupsdidnotpresentanyconditions
which could interfere with the research, such as chronic
diseases and drugs which could inﬂuence inﬂammatory
markers, uric acid levels, or metabolic syndrome parameters.
Thus, we were conﬁdent that the patients in this study had a
unique diagnosis of MS. Furthermore, subjects in this study
were exclusively women, which were paired by age, race,
smoking habit, and alcohol intake.
5. Conclusion
In conclusion, patients with MS presented several increased
inﬂammatory markers that were primarily associated with
insulin resistance and abdominal adiposity. The decrease
in anti-inﬂammatory protection and the increase in the
inﬂammatory process seem to be independent processes
in MS patients. Except for an inverse correlation with
adiponectinemia, serum uric acid levels did not correlate
with any other inﬂammatory marker. Although a transversal
study does not necessarily imply causality, it does suggest
a role of uric acid in the etiology of hypoadiponectinemia
in MS. Further investigations are needed to conﬁrm this
likelihood.
Acknowledgment
This work was supported by the National Council of
Brazilian Research, CNPq.6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
References
[1] G. M. Reaven, “Role of insulin resistance in human disease,”
Diabetes, vol. 37, no. 12, pp. 1595–1607, 1998.
[2] S. M. Grundy, “Metabolic syndrome pandemic,” Arteriosclero-
sis, Thrombosis, and Vascular Biology, vol. 28, no. 4, pp. 629–
636, 2008.
[3] A. Festa, R. D’Agostino, G. Howard, L. Mykk¨ a n e n ,R .P .T r a c y ,
and S. M. Haﬀner, “Chronic subclinical inﬂammation as
part of the insulin resistance syndrome: the insulin resistance
atherosclerosis study (IRAS),” Circulation, vol. 102, no. 1, pp.
42–47, 2000.
[4] S. M. Haﬀner, “Insulin resistance, inﬂammation, and the
prediabetic state,” The American journal of cardiology, vol. 92,
pp. 18J–26J, 2003.
[5] K. Tamakoshi, H. Yatsuya, T. Kondo et al., “The metabolic
syndrome is associated with elevated circulating C-reactive
protein in healthy reference range, a systemic low-grade
inﬂammatory state,” International Journal of Obesity and
Related Metabolic Disorders, vol. 27, pp. 443–449, 2003.
[6] A. C. Santos, C. Lopes, J. T. Guimar˜ aes, and H. Barros,
“Central obesity as a major determinant of increased high-
sensitivity C-reactive protein in metabolic syndrome,” Inter-
national Journal of Obesity, vol. 29, no. 12, pp. 1452–1456,
2005.
[7] P. Trayhurn and I. S. Wood, “Adipokines: inﬂammation and
the pleiotropic role of white adipose tissue,” British Journal of
Nutrition, vol. 92, no. 3, pp. 347–355, 2004.
[8] T. Yokota, K. Oritani, I. Takahashi et al., “Adiponectin, a new
member of the family of soluble defense collagens, negatively
regulates the growth of myelomonocytic progenitors and the
functions of macrophages,” Blood, vol. 96, no. 5, pp. 1723–
1732, 2000.
[9] N. Ouchi, S. Kihara, Y. Arita et al., “Novel modulator for
endothelial adhesion molecules: adipocyte-derived plasma
protein adiponectin,” Circulation, vol. 100, no. 25, pp. 2473–
2476, 1999.
[10] N.Ouchi,S.Kihara,Y.Aritaetal.,“Adiponectin,anadipocyte-
derived plasma protein, inhibits endothelial NF-kappaB sig-
naling through a cAMP-dependent pathway,” Circulation, vol.
102, no. 11, pp. 1296–1301, 2000.
[11] K. Hotta, T. Funahashi, N. L. Bodkin et al., “Circulating
concentrations of the adipocyte protein adiponectin are
decreased in parallel with reduced insulin sensitivity during
the progression to type 2 diabetes in rhesus monkeys,”
Diabetes, vol. 50, no. 5, pp. 1126–1133, 2001.
[12] P. A. Kern, S. Ranganathan, C. Li, L. Wood, and G. Ran-
ganathan, “Adipose tissue tumor necrosis factor and IL-6
expression in human obesity and insulin resistance,” American
Journal of Physiology, vol. 280, pp. E745–E751, 2001.
[13] N. Maeda, M. Takahashi, T. Funahashi et al., “PPARγ ligands
increaseexpressionandplasmaconcentrationsofadiponectin,
an adipose-derived protein,” Diabetes, vol. 50, no. 9, pp. 2094–
2099, 2001.
[14] Y. Arita, S. Kihara, N. Ouchi et al., “Paradoxical decrease of an
adipose-speciﬁc protein, adiponectin, in obesity,” Biochemical
and Biophysical Research Communications, vol. 257, no. 1, pp.
79–83, 1999.
[15] K. Hotta, T. Funahashi, Y. Arita et al., “Plasma concentrations
of a novel, adipose-speciﬁc protein, adiponectin, in type 2
diabetic patients,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 20, no. 6, pp. 1595–1599, 2000.
[16] Y. Iwashima, T. Katsuya, K. Ishikawa et al., “Hypoadiponect-
inemia is an independent risk factor for hypertension,”
Hypertension, vol. 43, no. 6, pp. 1318–1323, 2004.
[17] A. M. Xydakis, C. C. Case, P. H. Jones et al., “Adiponectin,
inﬂammation, and the expression of the metabolic syndrome
in obese individuals: the impact of rapid weight lose through
caloric restriction,” Journal of Clinical Endocrinology and
Metabolism, vol. 89, no. 6, pp. 2697–2703, 2004.
[18] M. Santaniemi, Y. A. Kes¨ aniemi, and O. Ukkola, “Low plasma
adiponectin concentration is an indicator of the metabolic
syndrome,” European Journal of Endocrinology, vol. 155, no. 5,
pp. 745–750, 2006.
[19] N. Ouchi, S. Kihara, T. Funahashi et al., “Reciprocal associa-
tion of C-reactive protein with adiponectin in blood stream
and adipose tissue,” Circulation, vol. 107, no. 5, pp. 671–674,
2003.
[20] J. Vendrell, M. Broch, N. Vilarrasa et al., “Resistin, adi-
ponectin, ghrelin, leptin, and proinﬂammatory cytokines:
relationships in obesity,” Obesity Research, vol. 12, no. 6, pp.
962–971, 2004.
[21] C. Herder, H. Hauner, B. Haastert et al., “Hypoadiponectine-
mia and proinﬂammatory state: two sides of the same coin?
Results from the Cooperative Health Research in the Region
of Augsburg Survey 4 (KORA S4),” Diabetes Care, vol. 29, no.
7, pp. 1626–1631, 2006.
[22] J. Kanellis and D. H. Kang, “Uric acid as a mediator of
endothelial dysfunction, inﬂammation, and vascular disease,”
Seminars in Nephrology, vol. 25, no. 1, pp. 39–42, 2005.
[23] T. Nakagawa, H. Hu, S. Zharikov et al., “A causal role for
uric acid in fructose-induced metabolic syndrome,” American
Journal of Physiology, vol. 290, no. 3, pp. F625–F631, 2006.
[24] A. N. C. Sim˜ ao, J. B. Dichi, D. S. Barbosa, R. Cecchini, and
I. Dichi, “Inﬂuence of uric acid and γ-glutamyltransferase on
total antioxidant capacity and oxidative stress in patients with
metabolic syndrome,” Nutrition, vol. 24, no. 7-8, pp. 675–681,
2008.
[25] D. R. Jacobs Jr., “Executive summary of the third report of
the National Cholesterol Education Program (NCEP) expert
panel on detection, evaluation, and treatment of high blood
cholesterol in adults (adult treatment panel III),” Journal of the
American Medical Association, vol. 285, no. 19, pp. 2486–2497,
2001.
[26] S. M. Haﬀner, H. Miettinen, and M. P. Stern, “The homeosta-
sis model in the San Antonio Heart Study,” Diabetes Care, vol.
20, no. 7, pp. 1087–1092, 1997.
[27] K. Matsushita, H. Yatsuya, K. Tamakoshi et al., “Compari-
son of circulating adiponectin and proinﬂammatory mark-
ers regarding their association with metabolic syndrome
in Japanese men,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 26, no. 4, pp. 871–876, 2006.
[28] K.E.WellenandG.S.Hotamisligil,“Inﬂammation,stress,and
diabetes,” Journal of Clinical Investigation, vol. 115, no. 5, pp.
1111–1119, 2005.
[29] H. Tilg and A. R. Moschen, “Adipocytokines: mediators
linking adipose tissue, inﬂammation and immunity,” Nature
Reviews Immunology, vol. 6, no. 10, pp. 772–783, 2006.
[30] P.Kallio,M.Kolehmainen,D.E.Laaksonenetal.,“Dietarycar-
bohydrate modiﬁcation induces alterations in gene expression
in abdominal subcutaneous adipose tissue in persons with
the metabolic syndrome: the FUNGENUT Study,” American
Journal of Clinical Nutrition, vol. 85, no. 5, pp. 1417–1427,
2007.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
[31] J. S. Yudkin, M. Kumari, S. E. Humphries, and V. Mohamed-
Ali, “Inﬂammation, obesity, stress and coronary heart disease:
is interleukin-6 the link?” Atherosclerosis, vol. 148, no. 2, pp.
209–214, 2000.
[32] A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and
P. M. Ridker, “C-reactive protein, interleukin 6, and risk of
developing type 2 diabetes mellitus,” Journal of the American
Medical Association, vol. 286, no. 3, pp. 327–334, 2001.
[33] V. Mohamed-Ali, S. Goodrick, A. Rawesh et al., “Subcuta-
neous adipose tissue releases interleukin-6, but not tumor
necrosis factor-α,i nv i v o , ”Journal of Clinical Endocrinology
and Metabolism, vol. 82, no. 12, pp. 4196–4200, 1997.
[34] S. K. Fried, D. A. Bunkin, and A. S. Greenberg, “Omental
and subcutaneous adipose tissues of obese subjects release
interleukin-6: depot diﬀerence and regulation by glucocorti-
coid,” Journal of Clinical Endocrinology and Metabolism, vol.
83, no. 3, pp. 847–850, 1998.
[35] A. Onat, B. Uzunlar, G. Hergenc ¸ et al., “Cross-sectional study
of complement C3 as a coronary risk factor among men and
women,” Clinical Science, vol. 108, no. 2, pp. 129–135, 2005.
[36] J. W¨ a r n b e r g ,E .N o v a ,L .A .M o r e n oe ta l . ,“ I n ﬂ a m m a t o r y
proteins are related to total and abdominal adiposity in a
healthy adolescent population: the AVENA Study,” American
Journal of Clinical Nutrition, vol. 84, no. 3, pp. 505–512, 2006.
[37] J. Danesh, P. Whincup, M. Walker et al., “Low grade inﬂam-
mation and coronary heart disease: prospective study and
updated meta-analyses,” British Medical Journal, vol. 321, no.
7255, pp. 199–204, 2000.
[38] W.-S. Yang, W.-J. Lee, T. Funahashi et al., “Plasma adiponectin
levels in overweight and obese Asians,” Obesity Research, vol.
10, no. 11, pp. 1104–1110, 2002.
[39] W. S. Waring, D. J. Webb, and S. R. J. Maxwell, “Uric acid as
a risk factor for cardiovascular disease,” QJM, vol. 93, no. 11,
pp. 707–713, 2000.
[40] D. A. Patel, S. R. Srinivasan, J. H. Xu, W. Chen, and G. S.
Berenson, “Adiponectin and its correlates of cardiovascular
risk in young adults: the Bogalusa Heart Study,” Metabolism,
vol. 55, no. 11, pp. 1551–1557, 2006.